Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany
Authors
Keywords
-
Journal
Journal for ImmunoTherapy of Cancer
Volume 9, Issue 2, Pages e001701
Publisher
BMJ
Online
2021-02-20
DOI
10.1136/jitc-2020-001701
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Anti-PD-1 and Novel Combinations in the Treatment of Melanoma—An Update
- (2020) Frank Friedrich Gellrich et al. Journal of Clinical Medicine
- Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls
- (2020) Eli P. Darnell et al. Current Oncology Reports
- Two roads for oncolytic immunotherapy development
- (2019) Howard L. Kaufman et al. Journal for ImmunoTherapy of Cancer
- High response rates for T-VEC in early metastatic melanoma (stage IIIB/C-IVM1a)
- (2019) Viola Franke et al. INTERNATIONAL JOURNAL OF CANCER
- Talimogene laherparepvec (T‐ VEC ) in advanced melanoma: complete response in a heart and kidney transplant patient. A case report
- (2019) J. Ressler et al. BRITISH JOURNAL OF DERMATOLOGY
- Response to the Rechallenge With Talimogene Laherparepvec (T-VEC) After Ipilimumab/Nivolumab Treatment in Patient With Cutaneous Malignant Melanoma Who Initially Had a Progression on T-VEC With Pembrolizumab
- (2019) Muhammad Z. Afzal et al. JOURNAL OF IMMUNOTHERAPY
- Real-World Outcomes of Talimogene Laherparepvec Therapy: A Multi-Institutional Experience
- (2019) Raphael J. Louie et al. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
- Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma
- (2019) Praveen K. Bommareddy et al. OncoImmunology
- Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma
- (2019) Jason Chesney et al. BRITISH JOURNAL OF CANCER
- Correlates of response and outcomes with talimogene laherperpvec
- (2019) Alice Y. Zhou et al. JOURNAL OF SURGICAL ONCOLOGY
- Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
- (2019) Caroline Robert et al. LANCET ONCOLOGY
- Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
- (2019) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma
- (2019) Robert H. I. Andtbacka et al. Journal for ImmunoTherapy of Cancer
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2019) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma
- (2019) Robert H.I. Andtbacka et al. EBioMedicine
- Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2019) O Michielin et al. ANNALS OF ONCOLOGY
- Determinants of combination GM-CSF immunotherapy and oncolytic virotherapy success identified through in silico treatment personalization
- (2019) Tyler Cassidy et al. PLoS Computational Biology
- Mapping the preclinical to clinical evidence and development trajectory of the oncolytic virus talimogene laherparepvec (T-VEC): a systematic review
- (2019) Manoj Lalu et al. BMJ Open
- Oncolytic Viruses for Cancer Therapy: Barriers and Recent Advances
- (2019) Meijun Zheng et al. Molecular Therapy-Oncolytics
- Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series
- (2018) Lillian Sun et al. Journal for ImmunoTherapy of Cancer
- Management of In-Transit Melanoma: We Need Some High-Quality Data
- (2018) David E. Gyorki Journal of Oncology Practice
- Real-World Use of Talimogene Laherparepvec in German Patients with Stage IIIB to IVM1a Melanoma: A Retrospective Chart Review and Physician Survey
- (2018) Peter Mohr et al. ADVANCES IN THERAPY
- Talimogene Laherparepvec (TVEC) for the Treatment of Advanced Melanoma: A Single-Institution Experience
- (2018) Matthew C. Perez et al. ANNALS OF SURGICAL ONCOLOGY
- Economic Evaluation of Talimogene Laherparepvec Plus Ipilimumab Combination Therapy vs Ipilimumab Monotherapy in Patients With Advanced Unresectable Melanoma
- (2018) Abdulaali R. Almutairi et al. JAMA Dermatology
- Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials
- (2017) Howard L. Kaufman et al. Journal for ImmunoTherapy of Cancer
- Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma
- (2016) Robert H. I. Andtbacka et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial
- (2016) Kevin Harrington et al. OncoTargets and Therapy
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started